Cargando…

Leveraging the utility of pharmacogenomics in psychiatry through clinical decision support: a focus group study

BACKGROUND: Pharmacogenomics is starting to build momentum in clinical utility, perhaps the most in mental and behavioral healthcare. However, efficient delivery of this information to the point of prescribing remains a significant challenge. Clinical decision support has an opportunity to address t...

Descripción completa

Detalles Bibliográficos
Autores principales: Goodspeed, Andrew, Kostman, Nicolas, Kriete, Trenton E., Longtine, Joel W., Smith, Sean M., Marshall, Peregrin, Williams, Wesley, Clark, Cheryl, Blakeslee, Weston W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688280/
https://www.ncbi.nlm.nih.gov/pubmed/31413721
http://dx.doi.org/10.1186/s12991-019-0237-3
_version_ 1783442854870253568
author Goodspeed, Andrew
Kostman, Nicolas
Kriete, Trenton E.
Longtine, Joel W.
Smith, Sean M.
Marshall, Peregrin
Williams, Wesley
Clark, Cheryl
Blakeslee, Weston W.
author_facet Goodspeed, Andrew
Kostman, Nicolas
Kriete, Trenton E.
Longtine, Joel W.
Smith, Sean M.
Marshall, Peregrin
Williams, Wesley
Clark, Cheryl
Blakeslee, Weston W.
author_sort Goodspeed, Andrew
collection PubMed
description BACKGROUND: Pharmacogenomics is starting to build momentum in clinical utility, perhaps the most in mental and behavioral healthcare. However, efficient delivery of this information to the point of prescribing remains a significant challenge. Clinical decision support has an opportunity to address this void by integrating pharmacogenomics into the clinician workflow. METHODS: To address the specific needs of mental health clinicians at the point of care, we conducted 3 focus groups with a total of 16 mental health clinicians. Each 1-h focus group was designed to identify the desired clinical decision support features, with a particular interest in pharmacogenomics, and potential negative or unintended consequences of clinical decision support integration at the point of care in a mental healthcare setting. We implemented an iterative design to expand upon knowledge generated in prior focus groups. The results from the guided discussion in the first focus group were used to develop a mental health clinical decision support prototype. This prototype was then presented during the next two focus groups to drive the discussion. RESULTS: This study has identified main themes related to the desired clinical decision support features of mental health clinicians, the use of pharmacogenomics in practice, and unintended and negative consequences of clinical decision support integration at the point of care. Clinicians desire a more complete picture of the medication history of patients and guidance to choose medications in relation to cost, insurance coverage, and pharmacogenetics interactions. Mental health clinicians agreed that pharmacogenetics is useful and impacts their prescribing decisions when the data are available. Several negative consequences of clinical decision support integration were identified including alert fatigue and frustration using the tool. Several points of contention were related to the integration of the clinical decision support with the electronic health record, including bidirectional flow of information, speed, location within workflow, and potential incompleteness of information. CONCLUSIONS: We have identified general and unique considerations of mental health clinicians with regard to clinical decision support. Clinical decision support that incorporates desired features while avoiding negative and unintended consequences will increase clinician usage and will have the potential to improve the care of patients.
format Online
Article
Text
id pubmed-6688280
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66882802019-08-14 Leveraging the utility of pharmacogenomics in psychiatry through clinical decision support: a focus group study Goodspeed, Andrew Kostman, Nicolas Kriete, Trenton E. Longtine, Joel W. Smith, Sean M. Marshall, Peregrin Williams, Wesley Clark, Cheryl Blakeslee, Weston W. Ann Gen Psychiatry Primary Research BACKGROUND: Pharmacogenomics is starting to build momentum in clinical utility, perhaps the most in mental and behavioral healthcare. However, efficient delivery of this information to the point of prescribing remains a significant challenge. Clinical decision support has an opportunity to address this void by integrating pharmacogenomics into the clinician workflow. METHODS: To address the specific needs of mental health clinicians at the point of care, we conducted 3 focus groups with a total of 16 mental health clinicians. Each 1-h focus group was designed to identify the desired clinical decision support features, with a particular interest in pharmacogenomics, and potential negative or unintended consequences of clinical decision support integration at the point of care in a mental healthcare setting. We implemented an iterative design to expand upon knowledge generated in prior focus groups. The results from the guided discussion in the first focus group were used to develop a mental health clinical decision support prototype. This prototype was then presented during the next two focus groups to drive the discussion. RESULTS: This study has identified main themes related to the desired clinical decision support features of mental health clinicians, the use of pharmacogenomics in practice, and unintended and negative consequences of clinical decision support integration at the point of care. Clinicians desire a more complete picture of the medication history of patients and guidance to choose medications in relation to cost, insurance coverage, and pharmacogenetics interactions. Mental health clinicians agreed that pharmacogenetics is useful and impacts their prescribing decisions when the data are available. Several negative consequences of clinical decision support integration were identified including alert fatigue and frustration using the tool. Several points of contention were related to the integration of the clinical decision support with the electronic health record, including bidirectional flow of information, speed, location within workflow, and potential incompleteness of information. CONCLUSIONS: We have identified general and unique considerations of mental health clinicians with regard to clinical decision support. Clinical decision support that incorporates desired features while avoiding negative and unintended consequences will increase clinician usage and will have the potential to improve the care of patients. BioMed Central 2019-08-08 /pmc/articles/PMC6688280/ /pubmed/31413721 http://dx.doi.org/10.1186/s12991-019-0237-3 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Primary Research
Goodspeed, Andrew
Kostman, Nicolas
Kriete, Trenton E.
Longtine, Joel W.
Smith, Sean M.
Marshall, Peregrin
Williams, Wesley
Clark, Cheryl
Blakeslee, Weston W.
Leveraging the utility of pharmacogenomics in psychiatry through clinical decision support: a focus group study
title Leveraging the utility of pharmacogenomics in psychiatry through clinical decision support: a focus group study
title_full Leveraging the utility of pharmacogenomics in psychiatry through clinical decision support: a focus group study
title_fullStr Leveraging the utility of pharmacogenomics in psychiatry through clinical decision support: a focus group study
title_full_unstemmed Leveraging the utility of pharmacogenomics in psychiatry through clinical decision support: a focus group study
title_short Leveraging the utility of pharmacogenomics in psychiatry through clinical decision support: a focus group study
title_sort leveraging the utility of pharmacogenomics in psychiatry through clinical decision support: a focus group study
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688280/
https://www.ncbi.nlm.nih.gov/pubmed/31413721
http://dx.doi.org/10.1186/s12991-019-0237-3
work_keys_str_mv AT goodspeedandrew leveragingtheutilityofpharmacogenomicsinpsychiatrythroughclinicaldecisionsupportafocusgroupstudy
AT kostmannicolas leveragingtheutilityofpharmacogenomicsinpsychiatrythroughclinicaldecisionsupportafocusgroupstudy
AT krietetrentone leveragingtheutilityofpharmacogenomicsinpsychiatrythroughclinicaldecisionsupportafocusgroupstudy
AT longtinejoelw leveragingtheutilityofpharmacogenomicsinpsychiatrythroughclinicaldecisionsupportafocusgroupstudy
AT smithseanm leveragingtheutilityofpharmacogenomicsinpsychiatrythroughclinicaldecisionsupportafocusgroupstudy
AT marshallperegrin leveragingtheutilityofpharmacogenomicsinpsychiatrythroughclinicaldecisionsupportafocusgroupstudy
AT williamswesley leveragingtheutilityofpharmacogenomicsinpsychiatrythroughclinicaldecisionsupportafocusgroupstudy
AT clarkcheryl leveragingtheutilityofpharmacogenomicsinpsychiatrythroughclinicaldecisionsupportafocusgroupstudy
AT blakesleewestonw leveragingtheutilityofpharmacogenomicsinpsychiatrythroughclinicaldecisionsupportafocusgroupstudy